← FDA DRUG APPROVALS

FDA ANDA · ANDA091349

EQUATE NICOTINE

nicotine polacrilex

Sponsor: PERRIGO R AND D

APPLICATION
ANDA091349
TYPE
ANDA
ORIGINAL APPROVAL
2011-07-20
LATEST ACTION
2024-03-15
ROUTE
ORAL, BUCCAL
DOSAGE FORM
GUM, CHEWING
MARKETING STATUS
Over-the-counter

Products

NICOTINE POLACRILEXOver-the-counter
NICOTINE POLACRILEX EQ 2MG BASE · GUM, CHEWING · BUCCAL

Approval history

2024-03-15Labeling · Supplement 15 · standardAP
2016-03-30Labeling · Supplement 8 · standardAP
2012-11-29Labeling · Supplement 7 · standardAP
2012-04-19Labeling · Supplement 3AP
2011-12-15Labeling · Supplement 2AP
2011-07-20OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →